Methods and composition for a binding molecule targeting cancer cells expressing SSX2 peptide 41-49 in HLA-A*0201 context

Abstract

Disclosed are Synovial Sarcoma X breakpoint 2 binding molecules and methods for their use in the detection and treatment of cancer.

What is claimed is: 
     
       1. A Synovial Sarcoma X breakpoint 2 (SSX2) binding molecule comprising:
 (i) 3 complementarity determining regions (CDRs) from the light chain variable region, wherein
 the first CDR comprises the sequence set forth in SEQ ID NO: 1, 
 the second CDR comprises the sequence set forth in SEQ ID NO: 2, and 
 the third CDR comprises the sequence set forth in SEQ ID NO: 3; and 
 
 (ii) 3 CDRs from the heavy chain variable region, wherein
 the first CDR comprises the sequence set forth in SEQ ID NO: 4, 
 the second CDR comprises the sequence set forth in SEQ ID NO: 5, and 
 the third CDR comprises the sequence set forth in SEQ ID NO: 6; 
 
 
       wherein the binding molecule targets a SSX2 peptide 41-49 (SEQ ID NO:07). 
     
     
       2. The SSX2 binding molecule of  claim 1 , wherein the binding molecule targets the SSX2 peptide 41-49 (SEQ ID NO: 7) in the context of human leukocyte antigen (HLA)-A*0201. 
     
     
       3. The SSX2 binding molecule of  claim 1 , wherein the binding molecule is an antibody, diabody, triabody, antigen binding fragment, bi-specific killer engager (BIKE), or tri-specific killer engager (TriKE). 
     
     
       4. The SSX2 binding molecule of  claim 3 , wherein the antibody is of IgG1, IgG2, IgG3, IgG4, IgM or IgA isotype. 
     
     
       5. A chimeric antigen receptor (CAR) comprising the Synovial Sarcoma X breakpoint 2 (SSX2) binding molecule of  claim 1 . 
     
     
       6. The CAR of  claim 5 , further comprising one or more activating intra-cellular domains derived from CD3zeta, CD28, 4-1BB, OX40L or 2B4. 
     
     
       7. A cell comprising the CAR of  claim 5 , wherein the cell is a T cell or NK cell.